Company decided to remove CLIA test from Market.
Chart Review of Demographics and Clinical Outcomes and Physician Attitudes in Patients Who Have Received the Microculture Kinetic (MiCK) Apoptosis Test
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · DiaTech
observational
0
2 countries
2
Study Start
April 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2016
Actual (reported)Study Completion
June 2016
Actual (reported)Recently an automated test for measuring cancer cell death in the presence of chemotherapy has been developed. This test has been called the MiCK assay during the ten year development phase and is now called Correct Chemo. CorrectChemo provides the medical community and patients a way to determine the effects of different chemotherapies on individual cancer cells. MiCK assay has been proven to have clinical usefulness in two studies. In one study using multiple types of cancer, physicians used the MiCK assay in 63% of the patients. If the physician used the results to prescribe the chemotherapy treatment, the patients' response rate, time to the disease getting worse, and overall survival were all significantly better compared to patients whose physicians did not use the results. In another study of breast cancer patients, physicians used the MiCK assay in 74% of patients. If the results were used when planning chemotherapy, response rate and time to the disease started getting worse were all significantly better compared to patients whose physicians did not use the results of the MiCK assay The purpose of this study is to compare the outcomes of patients who have had the MiCK assay (CorrectChemo) with tumor types, physician attitudes towards the test, and how the physicians used the test. This study will be gathering this data by reviewing medical charts.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2014
Date type not reportedThis date has not been verified as actual or estimated.
April 23, 2014
Actual (reported)May 14, 2014
Actual (reported)June 2016
Actual (reported)June 2016
Actual (reported)Clinical composite outcomes
To determine the clinical outcomes (response rates, time to progression, and overall survival) in patients who have had a MiCK assay (CorrectChemo.) This will be correlated with pattern of physician use of the assay.
6 months
Clinical composite outcomes
To determine the clinical outcomes (response rates, time to progression, and overall survival) in patients who have had a MiCK assay (CorrectChemo). This will be correlated with pattern of physician use of the assay.
12 months
Clinical composite outcomes
To determine the clinical outcomes (response rates, time to progression, and overall survival) in patients who have had a MiCK assay (CorrectChemo.) This will be correlated with pattern of physician use of the assay.
24 months
How often Physicians use MiCK assay (CorrectChemo) results in patient treatment plan
6 months
How often Physicians use MiCK assay (CorrectChemo) results in patient treatment plan
12 months
How often Physicians use MiCK assay (CorrectChemo) results in patient treatment plan
24 months
Physician attitudes
6 months
Physician attitudes
12 months
Physician attitudes
24 months
Patients with pathological diagnoses of cancer or leukemia who have had a MiCK assay (CorrectChemo) test performed
An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with pathological diagnoses of cancer or leukemia who have had a MiCK assay (CorrectChemo) performed
DiaTech Oncology
Franklin, Tennessee, 37069, United States
DiaTech Oncology
Montreal, Quebec, H2X3P9, Canada
Allan Hallquist, MD
Pierian Biosciences
0 participants (actual enrollment reported by the registry).
First Submitted
April 23, 2014
First Posted
May 14, 2014
Study Start
April 2014
Date type not reportedThis date has not been verified as actual or estimated.
Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis Cancers
Contact the study team to confirm eligibility.
Primary Completion
June 2016
Actual (reported)Study Completion
June 2016
Actual (reported)Last Updated
July 21, 2016
Record last verified: 2016-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: